Epizyme (NASDAQ:EPZM) – Equities researchers at SunTrust Banks lifted their Q2 2018 EPS estimates for Epizyme in a note issued to investors on Tuesday, March 13th, Zacks Investment Research reports. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will post earnings per share of ($0.59) for the quarter, up from their previous forecast of ($0.60). SunTrust Banks has a “Buy” rating and a $27.00 price objective on the stock. SunTrust Banks also issued estimates for Epizyme’s Q4 2018 earnings at ($0.69) EPS, FY2018 earnings at ($2.47) EPS, FY2019 earnings at ($3.14) EPS, FY2020 earnings at ($1.17) EPS, FY2021 earnings at $1.89 EPS and FY2022 earnings at $3.25 EPS.
Epizyme (NASDAQ:EPZM) last released its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.05. Epizyme’s quarterly revenue was down 100.0% compared to the same quarter last year.
Other equities research analysts also recently issued research reports about the company. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. ValuEngine upgraded Epizyme from a “sell” rating to a “hold” rating in a report on Tuesday, February 13th. Roth Capital began coverage on Epizyme in a report on Thursday, February 1st. They issued a “buy” rating and a $24.00 price objective for the company. Oppenheimer set a $26.00 price objective on Epizyme and gave the company a “buy” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $23.50.
Shares of EPZM stock traded down $1.50 on Friday, reaching $14.85. 514,308 shares of the stock were exchanged, compared to its average volume of 442,865. The company has a market cap of $1,031.18, a P/E ratio of -6.81 and a beta of 1.96. Epizyme has a one year low of $9.30 and a one year high of $21.40.
Several institutional investors have recently made changes to their positions in EPZM. The Manufacturers Life Insurance Company increased its holdings in shares of Epizyme by 3.3% in the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after acquiring an additional 1,068 shares in the last quarter. Swiss National Bank increased its holdings in shares of Epizyme by 25.5% in the third quarter. Swiss National Bank now owns 83,700 shares of the biopharmaceutical company’s stock worth $1,594,000 after acquiring an additional 17,000 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of Epizyme by 12.6% in the third quarter. New York State Common Retirement Fund now owns 46,600 shares of the biopharmaceutical company’s stock worth $888,000 after acquiring an additional 5,200 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Epizyme by 2.6% in the third quarter. Bank of New York Mellon Corp now owns 202,178 shares of the biopharmaceutical company’s stock worth $3,852,000 after acquiring an additional 5,140 shares in the last quarter. Finally, Macquarie Group Ltd. increased its holdings in shares of Epizyme by 105.5% in the third quarter. Macquarie Group Ltd. now owns 41,100 shares of the biopharmaceutical company’s stock worth $783,000 after acquiring an additional 21,100 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.
In other Epizyme news, COO Matthew Ros sold 72,264 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the sale, the chief operating officer now directly owns 74,867 shares in the company, valued at $1,245,038.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.20% of the stock is owned by corporate insiders.
WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/epizyme-inc-epzm-expected-to-earn-q2-2018-earnings-of-0-59-per-share.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Get a free copy of the Zacks research report on Epizyme (EPZM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.